Financials Bio-Works Technologies AB
Equities
BIOWKS
SE0007387089
Medical Equipment, Supplies & Distribution
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.8 SEK | -1.75% | -4.76% | -60.56% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 176.7 | 243.9 | 276.8 | 959 | 736.4 | 276.8 |
Enterprise Value (EV) 1 | 122.7 | 167.5 | 243.7 | 856.3 | 670.6 | 237.4 |
P/E ratio | -4.64 x | -5.76 x | -6.15 x | -66.3 x | -16.4 x | -4.51 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 26.9 x | 43.8 x | 38.3 x | 17 x | 17.8 x | 6.3 x |
EV / Revenue | 18.7 x | 30.1 x | 33.7 x | 15.2 x | 16.2 x | 5.41 x |
EV / EBITDA | -3.86 x | -4.01 x | -5.36 x | -81.8 x | -14.4 x | -4.17 x |
EV / FCF | -5.31 x | -6.58 x | -8.96 x | -104 x | -26.3 x | -6.09 x |
FCF Yield | -18.8% | -15.2% | -11.2% | -0.96% | -3.81% | -16.4% |
Price to Book | 2.87 x | 2.97 x | 7.39 x | 8.84 x | 10.9 x | 6.29 x |
Nbr of stocks (in thousands) | 19,336 | 30,416 | 30,416 | 34,874 | 35,069 | 38,980 |
Reference price 2 | 9.140 | 8.020 | 9.100 | 27.50 | 21.00 | 7.100 |
Announcement Date | 4/26/19 | 4/28/21 | 4/28/21 | 4/27/22 | 4/28/23 | 4/22/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 6.563 | 5.572 | 7.234 | 56.36 | 41.32 | 43.9 |
EBITDA 1 | -31.81 | -41.75 | -45.5 | -10.47 | -46.67 | -56.89 |
EBIT 1 | -33.51 | -42.13 | -45.65 | -10.96 | -47.14 | -57.5 |
Operating Margin | -510.56% | -756.07% | -631.1% | -19.44% | -114.09% | -131% |
Earnings before Tax (EBT) 1 | -37.96 | -42.11 | -45.02 | -9.37 | -44.7 | -54.73 |
Net income 1 | -37.96 | -42.11 | -45.02 | -12.94 | -44.95 | -56.82 |
Net margin | -578.32% | -755.8% | -622.33% | -22.96% | -108.79% | -129.44% |
EPS 2 | -1.970 | -1.392 | -1.480 | -0.4147 | -1.284 | -1.573 |
Free Cash Flow 1 | -23.09 | -25.46 | -27.21 | -8.227 | -25.53 | -38.97 |
FCF margin | -351.83% | -456.93% | -376.1% | -14.6% | -61.79% | -88.78% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 4/26/19 | 4/28/21 | 4/28/21 | 4/27/22 | 4/28/23 | 4/22/24 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2020 S2 | 2021 S1 | 2022 S1 | 2022 S2 |
---|---|---|---|---|
Net sales 1 | 3.541 | 8.288 | - | 23.18 |
EBITDA 1 | - | 9.6 | - | -22.04 |
EBIT 1 | - | 9.256 | - | -22.31 |
Operating Margin | - | 111.68% | - | -96.25% |
Earnings before Tax (EBT) 1 | - | - | - | -21.36 |
Net income 1 | - | - | -23.53 | -21.49 |
Net margin | - | - | - | -92.75% |
EPS | -0.7900 | - | -0.6700 | - |
Dividend per Share | - | - | - | - |
Announcement Date | 2/19/21 | 8/20/21 | 8/19/22 | 2/17/23 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 54.1 | 76.4 | 33.1 | 103 | 65.9 | 39.4 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -23.1 | -25.5 | -27.2 | -8.23 | -25.5 | -39 |
ROE (net income / shareholders' equity) | -47.2% | -58.6% | -75.3% | -17.7% | -51% | -102% |
ROA (Net income/ Total Assets) | -24.3% | -33.9% | -42.7% | -8.23% | -27.7% | -46.7% |
Assets 1 | 156.5 | 124.3 | 105.3 | 157.2 | 162.1 | 121.6 |
Book Value Per Share 2 | 3.190 | 2.700 | 1.230 | 3.110 | 1.930 | 1.130 |
Cash Flow per Share 2 | 2.800 | 2.510 | 1.090 | 2.950 | 1.870 | 1.010 |
Capex 1 | 0.78 | 0.22 | 0.33 | 0.94 | 1.12 | 0.86 |
Capex / Sales | 11.9% | 3.95% | 4.51% | 1.67% | 2.72% | 1.96% |
Announcement Date | 4/26/19 | 4/28/21 | 4/28/21 | 4/27/22 | 4/28/23 | 4/22/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-60.56% | 10.28M | |
-3.62% | 184B | |
-0.37% | 108B | |
-2.60% | 67.82B | |
+3.42% | 51.05B | |
+9.73% | 44.67B | |
+3.40% | 41.78B | |
+2.23% | 26.78B | |
+4.20% | 26.59B | |
+15.23% | 25.86B |
- Stock Market
- Equities
- BIOWKS Stock
- Financials Bio-Works Technologies AB